However, genetic depletion of FGF2 (52) or pharmacological blockade of the FGFR1 pathway (53, 54) in HSCs significantly inhibits carbon tetrachloride– or lipopolysaccharide-induced hepatic cirrhosis and fibrosis. The gene discussed is FGF2; the disease is Cirrhosis.